DV
Dividend Vision

FATE — Fate Therapeutics Inc

Fate Therapeutics Inc (FATE)

Total return is -61.2% over the past 12.9 years, 530.1 points behind SPY at 468.9%. Its deepest 1-year drawdown was 41.6%.

FATE is an equity stock that does not function as a traditional dividend ETF. The security does not currently provide a distribution rate or regular dividend payments, making it unsuitable for income-focused investors seeking yield. This holding appeals primarily to growth-oriented investors interested in exposure to the biotechnology and therapeutics sector rather than those prioritizing dividend income.

FATE key facts

Asset type
Stock
Asset class
Equity
Inception date
10/01/2013
Last close
$2.57
Market cap
$324,034,528
Average volume
1995029.0
Beta
2.52
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.09